Total Cell Therapy — Total revenues
Gilead Sciences Total Cell Therapy — Total revenues decreased by 11.1% to $407.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 12.3%, from $464.00M to $407.00M. Over 3 years (FY 2022 to FY 2025), Total Cell Therapy — Total revenues shows an upward trend with a 8.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful market penetration, expanded clinical indications, or improved manufacturing capacity for cell-based therapies, while a decrease may signal increased competition, pricing pressure, or manufacturing bottlenecks.
Detailed definition
This metric represents the total gross revenue generated from the sale of cell therapy products within the company's onc...
Peer comparison
Comparable to oncology-focused revenue streams or advanced therapy medicinal product (ATMP) sales reported by other large-cap biopharmaceutical companies with specialized cell therapy divisions.
gild_segment_total_cell_therapy_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $364.75M | $364.75M | $364.75M | $364.75M | $467.25M | $467.25M | $467.25M | $467.25M | $480.00M | $521.00M | $485.00M | $487.00M | $464.00M | $485.00M | $432.00M | $458.00M | $407.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +28.1% | +0.0% | +0.0% | +0.0% | +2.7% | +8.5% | -6.9% | +0.4% | -4.7% | +4.5% | -10.9% | +6.0% | -11.1% |
| YoY Change | — | — | — | — | +28.1% | +28.1% | +28.1% | +28.1% | +2.7% | +11.5% | +3.8% | +4.2% | -3.3% | -6.9% | -10.9% | -6.0% | -12.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's total cell therapy — total revenues?
- Gilead Sciences (GILD) reported total cell therapy — total revenues of $407.00M in Q1 2026.
- How has Gilead Sciences's total cell therapy — total revenues changed year-over-year?
- Gilead Sciences's total cell therapy — total revenues decreased by 12.3% year-over-year, from $464.00M to $407.00M.
- What is the long-term trend for Gilead Sciences's total cell therapy — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's total cell therapy — total revenues has grown at a 8.0% compound annual growth rate (CAGR), from $1.46B to $1.84B.
- What does total cell therapy — total revenues mean?
- The total amount of money earned from selling cell therapy medical treatments.